A recent study by Ciudin et al explored the use of canagliflozin, a sodium-glucose cotransporter-2 inhibitor, as a treatment for PBH and completed SACSTs in 10 of the study patients to assess for nesidioblastosis [27]. Here, SLC5A2 is linked to familial hyperinsulinism.